



Medical Technology Association of Australia

ANNUAL REPORT

2021-22



Medical Technology
ASSOCIATION OF AUSTRALIA






ANNUAL REPORT CONTENT

06	ABOUT MTAA
08	CHAIR REPORT
12	CEO REPORT
15	POLICY ADVOCACY & COMMUNICATIONS
27	MEMBER ENGAGEMENT
40	COLLABORATION
43	INTEGRITY
44	MTAA MEMBERS
46	BOARD OF DIRECTORS
51	COMMITTEES
54	MEMBER FORUMS
56	WORKING / INTEREST GROUPS
58	COMMITTEE MEMBERS

KEY FACTS AND FIGURES

Global advances in medical technology over the past 20 years have resulted in:

-  **56%** reduction in hospital stays
-  **25%** decline in disability rate
-  **16%** decline in annual mortality and increased life expectancy of more than three years (approximately 3.2 years increase in life expectancy)



MTAA ACHIEVEMENTS



23

Media Releases
issued by MTAA



990

people attended
MTAA events



286

people attended
MedTech21 Virtual
Conference



116

MTAA Members with
87 Industry Members
and 29 Associate
Members



2,224

completed the online
Code of Practice
training



5,807

participants
completed MTAA
training



1,330

individuals
completed the
Operating Theatre
Protocols course



220

Committee, Forum
and Working Group
Representatives



followers
increased by
2,417
to 9,235



followers
increased by
148
to 1,971

ABOUT MTAA



MTAA represents manufacturers and suppliers of medical technology (MedTech) used in the diagnosis, prevention, treatment and management of disease and disability. MTAA members supply the majority of non-pharmaceutical products used in the treatment of disease and disability in Australia.

MedTech is diverse, ranging from familiar items such as syringes, wound dressings and wheelchairs through to more complex technologies including pacemakers, magnetic resonance imaging (MRI) machines, hip replacements, robotic surgery equipment and remote monitoring devices.

Our members play a vital role in providing healthcare professionals with essential education and training in the use of the more complex medical technologies to maximise patient health outcomes through the use of that technology.

Industry-sponsored fellowships and funding for research and development in hospitals, universities and research facilities helps to ensure the development and commercialisation of medical technology that meets contemporary healthcare needs and improves patient health and quality of life outcomes.

Associate members of MTAA are supporter or partner organisations and individuals who support the work of the industry along the entire MedTech value chain, all the way from concept through to patient utilisation.

They include legal, logistic and consulting practitioners, compliance agencies, health economists, researchers and universities, as well as industrial designers and product commercialisation specialists. They bring valuable expertise that enables MTAA to support its primary objective – to bring the benefits of technology to patients to ensure patient health outcomes and quality of life are improved.

Our work is to **champion medical technology for a healthier Australia**. When our work is done, **medical technology will be valued as a key driver of a healthier Australia**. We work with **integrity, collaboration, influence and leadership**.



ABOUT MTAA

OUR PEOPLE FROM 30 JUNE 2022

Ian Burgess	Chief Executive Officer
Paul Dale	Director, Policy
William Ko	Director, Business Operations & Company Secretary
Matthew Versi	Director, External Affairs & Communications
Jasjit Baveja	Associate Director, Policy
Stuart Anderson	Program Manager CTC-M
Neina Fahey	Code of Practice & Project Manager
Lee Harvey	Professional Development Manager
Jackie Lee	Events and Member Engagement Manager
Louie Radburn	Marketing Manager
Pravin Siriwardena	Policy Manager
Ranju Dhungel	Accounts Officer
Seni Murni	Administration Officer
Kerrie Zocchi	Executive Assistant
David Ross	Policy Advisor
Katherine Purcell	HR Advisor

MESSAGE

CHAIR REPORT



MAURICE BEN-MAYOR

CHAIR

PRESIDENT

STRYKER SOUTH PACIFIC

While the past financial year saw us experience a months long lockdown, continued stress on the health system and supply chain pressures, our industry rose to once again meet those challenges, support Australians and continue to provide life-changing and life-saving technologies, and the support services that enable them.

As this will be my last report as Chair of the MTAA Board, I wanted to take the opportunity to acknowledge the outstanding work of each and every one of our members throughout my tenure. We have met significant obstacles head on, represented our industry's vigour and tenacity in the face of continued attacks on patient access to, and doctor choice of, life-saving medical devices. We've also managed to steer our industry through an extremely dynamic political environment which has seen the most significant reforms to the Prostheses List, ever proposed.

We were faced with the very real possibility of seeing the Prostheses List abolished or completely gutted, which would have severely impacted countless patients across the country and saw many in the MedTech industry forced to make cuts or go out of business.

While not a silver bullet to our challenges, I am pleased to reflect back on the work that went into securing a four-year agreement signed between MTAA and the Commonwealth that put important guardrails in place to protect the patient access and doctor choice guarantee of the Prostheses List. MTAA was also successful in securing a signed, pre-election commitment from the new Minister for Health and Aged Care, the Hon Mark Butler MP, that the new Labor Government would deliver on the agreement.

It is also fair to say the significantly increased engagement of MTAA has helped to further contribute our positive reputation among, not just decision and policy-makers, but also key health sector stakeholders like doctors, hospitals and consumers which has helped us put patient-centric policy back at the centre of decision making.

CHAIR REPORT



MESSAGE CHAIR REPORT

“ We thank all our members for their contribution to the industry and the support that they provide to the many committees, forums and events held throughout the year.

Honouring Members Support

It is important to the MTAA Board that our membership base remains strong and diverse, and we thank all our members for their contribution to the industry and the support that they provide to the many committees, forums and events held throughout the year.

In 2021, MTAA celebrated 40 years of service - a significant milestone for the Association. We take the opportunity to recognise the many founding members who supported the Association since it's inception and thank the many other members who have demonstrated their commitment to the industry through continuous membership and participation.

This year we recognised:

5-Year Continuous Membership

Hologic (Australia & New Zealand) Pty Ltd
DHL Supply Chain (Australia) Pty Ltd
PharmaLex Pty Ltd
Bausch & Lomb (Australia) Pty Limited
Grey Innovation Pty Ltd
Prospitalia hTrak Pty Ltd

10-Year Continuous Membership

Horten Medical Pty Ltd
Tunstall Australasia Pty Ltd
Laminar Air Flow Pty Ltd

15-Year Continuous Membership

LifeHealthcare Pty Ltd

20-Year Continuous Membership

ConMed Australia Pty Ltd
Analytica Ltd

25-Year Continuous Membership

Boston Scientific Pty Ltd

40-Year Continuous Membership

3M Australia Pty Ltd
Abbott Vascular Pty Ltd
Alcon Laboratories (Australia) Pty Ltd
Allergan Australia Pty Ltd
Johnson & Johnson Medical Pty Ltd
Medtronic Australasia Pty Ltd
Smith & Nephew Pty Ltd
Terumo Australia Pty Ltd
W L Gore & Associates (Australia) Pty Ltd
Zimmer Biomet Pty Ltd



2021 Australian Industry Awards

The winner of the 15th Kerrin Rennie Award was announced during a virtual broadcast of the Australian Industry Awards, with the award going to Canon Medical for their Hi-Def Detector

The other Awards recipients included:

- Warren Bingham, MedTech International – Outstanding Achievement in MedTech;
- Emma Press, Medtronic – Women in MedTech Champion (individual);
- Baxter Healthcare – Women in MedTech Champion (company); and
- Fiona Lim, Medtronic- Emerging Women in Leadership Award.

Thank You and Farewell

I would like to thank my outstanding colleagues on the Board, the hard-working members of all of our committees and forums, and the MTAA team, particularly Ian Burgess as CEO, who has been a great support and counsel throughout my time as chair.

It has truly been a privilege to represent an industry that delivers so much good for Australians of all walks of life, and one that I'm proud to count myself as member.

Maurice Ben-Mayor
CHAIR

MESSAGE CEO REPORT



IAN BURGESS
CHIEF EXECUTIVE OFFICER
MEDICAL TECHNOLOGY ASSOCIATION OF AUSTRALIA

Advocacy & Engagement

We end this financial year with a new government in Canberra, and a new, diverse cohort of parliamentarians tasked with addressing the health challenges facing Australia.

Thanks to the increased engagement activity of MTAA, the industry is in a strong position to advocate for policy priorities of members. MTAA will start the new Parliamentary term with clear objectives and a long-term advocacy plan that will provide the strategic direction.

The re-constitution of the MTAA supported Parliamentary Friends of MedTech will provide industry with a direct channel of communication to members and senators of the 47th Parliament, particularly those new members with previous backgrounds in health.

MTAA's committees are currently working on three significant pieces work to support the advocacy activities of the industry, those include the Industry Messaging Framework with three distinct advocacy pillars, the development of a report to illustrate the community and economic value of medical technology in Australia, and a report exploring the yet-to-be-realised opportunities of 'connected health' to improve our health system.

MTAA plans to launch these key advocacy pieces in Parliament in 2023, with the support of the Parliamentary Friends of MedTech, members, patients and health sector supporters.

Member Focus

Total membership numbers have held steady this year with 116 members, this includes 87 corporate members and 29 associate members. This year we welcomed 5 new members including: Integra Lifesciences, Heraeus Medical Australia, Lima Orthopaedics Australia, Hydrix Services, MatOrtho. We also welcomed 2 new associate members this year: Commercial Eyes, and OneMD.

There are 9 committees currently operating and there are 112 positions. The 2021/22 committees are Public Affairs, Industry Policy, Reimbursement, Regulatory Affairs, Code Authority, Code Monitoring, Finance, Women in MedTech and the MedTech Conference Committee. Our sincere thanks to our members for their ongoing contribution to our committees, which is critical to our success.

Thanks to the increased engagement activity of MTAA, the industry is in a strong position to advocate for policy priorities of members.



MTAA team met with new Minister for Health and Aged Care, the Hon Mark Butler MP.

Financial Performance

MTAA achieved a net profit of \$28,709 for the twelve months to 30 June 2022 compared with the previous year's profit of \$349,505. This was a strong result given the continuing negative impact of COVID-19 on professional development and events income. In addition, expenditure increased by \$438,581, as a result of undertaking an important project to review the incidence of sexual misconduct that may be experienced by members' staff in their interactions with customers, in addition to our increased advocacy activities and also policy development in relation to the Protheses List.

Savings in premises costs of approximately 40% were achieved as a result of the relocation of the MTAA office to Macquarie Park in Sydney. With around twenty member companies located in the area, this relocation also provided enhanced opportunities for direct member engagement.

MTAA Team

Finally, I would like to acknowledge the outstanding efforts of the entire MTAA staff team during what was another busy and challenging year. MTAA has a small but dedicated and talented team that continue to go above and beyond to meet the needs of our members. The success of this past year would not have been possible without their hard work, dedication and adaptability to support all our members.

Ian Burgess
CHIEF EXECUTIVE OFFICER



*Dr Mike Freeman
MP, ALP.*



Milton Dick MP, Parliamentary Friends of MedTech

POLICY, ADVOCACY & COMMUNICATION

MTAA has used the Prostheses List reforms as an opportunity to further the MedTech industry's positive reputation among policy and decision-makers in the government, opposition and amongst the crossbench.

The formation of the Parliamentary Friends of MedTech (PFMT) has provided MTAA with a direct channel for advocacy among Members of Parliament and Senators. We are very pleased to say that former co-chair of the PFMT, the Hon Milton Dick MP, is now Speaker of the House of Representatives, and remains a strong supporter of ensuring patient access to life-saving medical devices.

MTAA's advocacy activities, the launch of the Protect Patient Choice campaign platform, the targeted media campaign and the continued collaboration with doctors, hospitals and consumer groups resulted in MTAA signing a four-year Prostheses List agreement that put in place guardrails for the government's reforms.

MTAA has also continued to advocate for member-specific matters at the ministerial, parliamentary and committee levels of government, ensuring MedTech's voice is part of the conversation.





ACHIEVEMENTS

- ✓ Successfully retained Prostheses List Agreement with Government
- ✓ Developed a higher profile with both sides of Government to advocate, influence and become a trusted advisor on key issues
- ✓ Successfully lobbied for MedTech professionals to have priority interstate travel during pandemic travel restrictions
- ✓ Gained commitment from Government to a One-Stop-Shop process for Clinical Trials
- ✓ Collaborated with partners to established the Clinical Translation and Commercialisation MedTech Program
- ✓ Collaborated with members to produce market intelligence in the Orthopaedics area
- ✓ Conducted a survey of members' staff to identify the incidence of sexual misconduct that may be experienced in their interactions with customers
- ✓ Successfully advocated for MedTech workers to have 1B vaccination priority
- ✓ Implementated a new user-friendly online training platform
- ✓ Successfully collaborated with key stakeholders to inform and shape Prostheses List policy
- ✓ Partnered with TGA on key training, events, committees and forums - bringing the conversation closer between Industry and Regulator
- ✓ New Code of Practice Edition 12 with introduction to Vendor Credentialing
- ✓ Led discussion and engaged with hospitals on a new vendor credentialing systems

Protheses List Reform

Having secured the continuation of the Protheses List (PL) in Financial Year 2020-21, Financial Year 2021-22 (FY22) still began with very significant risks for the industry. MTAA's goal was to ensure the Federal Budget May 2021 PL reform measure was properly understood and implemented in the best way for patients and industry. The Budget documents contained relatively little information and possible routes of implementation, and had the potential to result in very severe benefit cuts to the industry.

MTAA had several key objectives including:

- Ensuring that a weighted average not lowest public price was used as the benchmark
- Reintroducing a meaningful true floor for PL items being reduced to the public price which the Budget announcement had not provided
- Ensuring funding arrangements for cardiac technical support services and items removed from the PL
- Locking in clear methodologies for benefit calculations so there was no ambiguity or further savings on top of those announced
- Delivering improved PL listing reforms

The Budget announcement also required that industry provide data on public prices and volumes to the Independent Hospital Pricing Authority (IHPA). MTAA aimed to assist with this process but not to provide industry data until there were sufficient assurances by the government on the key reform issues.

To achieve these outcomes MTAA highlighted early significant concerns with possible directions of implementation of the reforms. MTAA also engaged



KPMG, its members and some non-members to collect the majority of public price data required by IHPA, enabling release once the Minister provided a letter of assurance about the reforms. Data was collected from over 70 sponsors representing over 90% of the value of the PL, allowing MTAA to model scenarios for negotiations.

In addition, MTAA met weekly with hospital, clinician and consumer peak body representatives to help align on positions. These groups provided supportive messages to the government on key matters of concern to MTAA. MTAA worked to educate IHPA about device pricing to ensure a reasonable recommendation on pricing methodology. MTAA also notified over 20 clinical colleges and professional societies about devices proposed for removal from the PL, which resulted in increased clinician engagement.

Data was collected from over 70 sponsors representing over 90% of the value of the PL, allowing MTAA to model scenarios for negotiations.



Ultimately in March 2022, MTAA signed a Memorandum of Understanding with the Minister for Health, the Hon Greg Hunt MP, that secured:

- A 7% floor above the public price on all PL reductions
- A guaranteed weighted average methodology using private volumes to set the public price
- A 12-month delay in any reductions to cardiac implantable electronic devices until technical services had been appropriately calculated
- A delay in removing General Use items by 12 months with phased benefit reductions across FY23
- Guaranteed no additional savings as a result of regrouping of PL items
- A commitment to a co-design process for new PL listing pathways

This was a significantly better outcome than was being proposed at various points in the discussions with the government.

MTAA also focused on ensuring timely and quality responses to the five consultation papers released in FY22:

- Consultation Paper No 1 Protheses List Purpose, Definitions and Scope August 2021
- IHPA Consultation Paper on a Methodology for Determining the Benchmark Price for Protheses in Australian Public Hospitals October 2021
- Consultation Paper 2(a) – Modernisation of Part B of the Protheses List February 2022
- Consultation Paper 3 – A modernised fit-for-purpose listing process February 2022
- Protheses List Monitoring and Evaluation Framework March 2022

MTAA also assisted in coordinating collective responses to regrouping recommendations across five different PL categories. Outcomes of these were still pending at the end of FY22 and require sustained focus into FY23.

Regulatory and Clinical Issues

MTAA's work is continuing to progress, ensuring regulatory reforms and the new and revised regulations and guidance documents continue to consider the industry perspective.

Achievements include:

- Continued high engagement with members. The Regulatory Affairs Forum membership has doubled in FY2022.
- Held 2 sold-out regulatory networking events to build the regulatory community in Australia.
- Achieved a reduction in fee for consent-to-supply applications related to Patient Information Leaflets and Patient Implant Cards, flexible supply options, and an expanded exemption list of devices.
- Successfully advocated for continued supply of surgical mesh products while the conformity assessment is under TGA review.
- Started MTAA/TGA regulatory workshops.
- Implementation of working groups to participate in TGA workshops including EU MDR, adverse event reporting, Unique Device Identification (UDI), approval timelines and Surgical Loan Kits (SLK).
- Continued participation and representation in TGA advertising, consultative committee and industry forums.
- Very strong TGA and MTAA collaboration.



Submissions

MTAA has submitted the following formal responses to Commonwealth consultations:

July 2021 - Proposed Refinements to the Regulation of Personalised Medical Devices.

August 2021 - Consultation Paper No 1 Prostheses List Purpose, Definitions and Scope

December 2021 - Discussion paper on potential for mandatory reporting of medical device adverse events by healthcare facilities in Australia

February 2022 - IHPA Consultation Paper on a Methodology for Determining the Benchmark Price for Prostheses in Australian Public Hospitals October 2021

February 2022 - Consultation Paper 2(a) – Modernisation of Part B of the Prostheses List Consultation Paper 3 – A modernised fit-for-purpose listing process

March 2022 - Prostheses List Monitoring and Evaluation Framework

March 2022 - Proposals for Changing the Therapeutic Goods Act

March 2022 - Consultation: Fees and Charges Proposal 2022-23



Industry Policy Committee

The role of the Industry Policy Committee is to promote initiatives (outside regulatory and reimbursement) which impact on industry development and sustainability and healthcare policy.

The Committee is responsible for developing policy positions and engaging with stakeholders on the digital healthcare agenda (including cybersecurity), the electronic patient record, mobile healthcare and registries. It is also responsible for supply chain issues, including traceability of medical devices.

MTPConnect initiatives, R&D, clinical trials and commercialisation all fall within the Committee's purview. Industry Policy Committee meetings are used to monitor the implementation of the \$30 million grant for SMEs under the MTAA Government Agreement.

The committee achieved several key milestones in the last 12 months:

- Engagement and consultation with the Australian Digital Health Agency – submitted MTAA's response to the Draft National Healthcare Interoperability Plan and discussed collated feedback from across different industries on the plan at the ADHA Draft National Healthcare Interoperability Plan Roundtable in March 2022.
- Engagement and consultation with the Department of Industry on Supply Chain challenges. In March 2022, MTAA provided collated feedback from members addressing the Department's Supply Chains Team's demand, supply and government communication questions. This helped the Supply Chain Team in their forward planning and securing of Rapid Antigen Tests (RATs) for Australia for the following 6-12 months.

- Meaningful and sustained engagement with procurement officials in each state. In the first half of 2022, MTAA and Healthshare NSW both signed off on a Joint Statement of Commitment to work together to improve procurement processes and outcomes. In July 2022 HSNSW made amendments, outlined in writing to 'best pricing' clause and 'eligible customer' definitions, based on MTAA feedback from members to minimise pricing information being shared with third parties outside NSW.
- Sustained advocacy in support of tax concessions for intellectual property commercialised in Australia. In August 2021, MTAA submitted a response as part of The Treasury's stakeholder consultation on the patent box policy design. Draft legislation was introduced to the House of Representatives in February 2022, with further amendments made prior to the May election, allowing more eligible applicants to access the scheme.


- Supporting MTPConnect, as an industry partner, launching The Clinical Translation and Commercialisation – MedTech Program. The Clinical Translation and Commercialisation - MedTech (CTCM) program is a \$19.75 million initiative funded by the Federal Government's Medical Research Future Fund and will offer financial assistance, educational support and infrastructure access to Australian small- to-medium-sized enterprises (SMEs).

Member Communications

MTAA has increased its utilisation of owned media channels to disseminate industry positive content across LinkedIn, Twitter and email in the form of infographics, video updates and industry news. This has yielded a significant increase in engagement on all MTAA communication platforms.

In line with its advocacy activities, MTAA undertook a series of digital media campaigns to promote the advances of MedTech helping the elderly, the importance of health checkups with the #DontWaitMate campaign, awareness of key dates and highlights of significant MedTech figures who have inspired the industry. MTAA maintained an average of 4 social media announcements per week on LinkedIn and Twitter throughout the 2021-22 period. MTAA has engaged the online community with thought-provoking content, aligned with MTAA's advocacy strategies, and continuing key conversations online after the event or activity has passed. As a result, the social media platforms of Twitter and LinkedIn have both shown increases of 148 and 2,417 followers.

Direct communication with members through MTAA's own branded newsletter is a key channel to inform members of the latest activities driven by the Association. During 2021-22 MTAA published 56 newsletters, including 22 Member Update Newsletters and 34 full database Email Blast Newsletters. High open rates suggest the quality of content was well received this year, with committees and third parties providing a richer array of exclusive news, opportunities and insights.




COMMS. BY NUMBERS IN THE LAST 12 MONTHS

 **4%**
INCREASE IN WEBSITE
PAGEVIEWS

 **56**
NEWSLETTERS SENT TO

 **8,382**
SUBSCRIBERS, AN
INCREASED BY 537

 **30%**
AVG. OPEN RATE FOR
NEWSLETTERS

 **9,235**
LINKEDIN FOLLOWERS.
GROWTH OF 2,417 NEW
FOLLOWERS

 **1,971**
TWITTER FOLLOWERS.
GROWTH OF 148 NEW
FOLLOWERS

 **34**
MEDIA RELEASES



A TOTAL OF NINE COMMITTEES,
SEVEN FORUMS AND SIX WORKING
GROUPS FORMED MTAA'S GOVERNANCE
STRUCTURE SUPPORTING KEY
INITIATIVES RELEVANT TO MEMBERS.

MEMBER ENGAGEMENT

Active participation of members is essential to MTAA achieving success. This year saw more than 220 member representatives contribute to the work of MTAA Committees, Forums and Working Groups.

MTAA Forums and Alliances provide opportunities for interaction between members on specific areas of interest affecting Industry. A total of nine active committees, seven forums and six working groups formed MTAA governance, supporting the key initiatives relevant to members.

Collaboration continued with growing support to the Connected Healthcare Advisory Group (CHAG). Operating under a new directive, aligned with the MTAA Strategic Plan 2022-25, CHAG provides a focus to the growing digitalisation of health.

In 2021-22, MTAA collaborated and supported MTPConnect with the delivery of the Clinical Translation and Commercialisation Program. A \$19.75 million initiative funded by the funded by the Australian Government's Medical Research Future Fund. MTAA played a vital role to support MTPConnect and other program delivery partnership, to shortlist viable medical technology with commercial potential.

Development of a new major area or business areas provides a voice for an important group of companies, broadens MTAA's scope of representation and addresses the issues facing MedTech today. This year we saw the resurgence of the SME Forum playing a key part to address major issues affecting or hindering SME members.

EVENTS BY NUMBERS

IN THE LAST 12 MONTHS

 **990**
INDIVIDUALS ATTENDED
MTAA EVENTS

 **778**
ATTENDEES LOGGED
ONTO ONLINE EVENTS

 **286**
ATTENDEES LOGGED
ON TO THE MEDTECH21
CONFERENCE

 **86**
ATTENDEES LOGGED
ON TO THE VALUE-
BASED PROCUREMENT
CONFERENCE

Events

Increasing engagement through events is a key activity MTAA maintains success in. MTAA attracts the best talent combined with a focus on the core issues affecting members. These topics are fed from committees and working groups to the MTAA events department to deliver memorable and engaging discussions and presentations.

MTAA continued to successfully adapt to the changing working climate by providing industry with a mix of face-to-face and virtual events. Eleven events were hosted with 990 attendees to MTAA events between 1 July 2021 – 30 June 2022.

EVENTS BY FORMAT

6 Virtual Events

- Value-Based Procurement Virtual Conference
- A Virtual Coffee Catchup with... Glow Up Careers
- Understanding your Mental Fitness in support of R U OK? Webinar
- PL Reform - Data Collection Webinar
- MedTech21 Virtual Conference
- MTAA MedTech Industry Awards

5 Face-to-Face Events

- Regulatory Affairs for Medical Devices Workshop
- EU MDR Update with MedTech Europe
- Regulatory Members-Only Networking Event
- Advertising and Promotion of Medical Devices and Effective Communication Workshop
- Regulatory Networking Event

JULY 2021

Value-Based Procurement Virtual Conference

15 July 2021

Members gathered for a one-day event on Value-Based Procurement (VBP) on 15 July discussing the value of health through procurement processes from around the world. Broken up into 4 sessions, Transform, Implement, Culture and Kick-off, the virtual event discussed changes in procurement practices for medical technologies, the cost saving through a new patient-centric system, the changing objectives of all stakeholders with aligned goals.

The event also explored the transformation of a VBP model and the shift in culture to health outcomes for patients and healthcare professionals. The day closed with a discussion on practical breakthroughs that can lead to a value-based procurement future.



AUGUST



A Virtual Coffee Catchup with Glow Up Careers

18 August 2021

Glow Up Careers Founder, Yvonne Kelly, and Cardinal Health Managing Director, Jane Crowe, shared their insights into how professionals can progress their career within their organisations, how they can better take control of their career path, and tips to transform their career into areas not traditionally considered by MedTech professionals.

SEPTEMBER



MTAA Webinar | Understanding your Mental Fitness in support of R U OK?

8 September 2021

MTAA hosted a special webinar for R U OK Day, themed on understanding mental life for busy corporate professionals. Sherpa Mike dived into the mental health challenges many have recently faced, the difficulties of juggling multiple life priorities and how individuals can cultivate their capacity to strike the right work/life balance.




PL Reform – Data Collection Webinar

28 September 2021

MTAA hosted a Prostheses List Reform webinar discussing data collection with Managing Directors, CEOs and nominated representatives with devices listed on the PL. This webinar reviewed PL reform processes, specifically the provision of Industry Data to the Independent Hospital Pricing Authority (IHPA), opening with a discussion from the Department and IHPA, followed by an industry-only discussion amongst members.

Understanding your Mental Fitness in support of R U OK? Webinar



NOVEMBER



MedTech21 Virtual Conference


MedTech21 Virtual Conference

17 November 2021

A record attendance of 286 MedTech professionals, academics and government representatives logged into the MedTech21 Virtual Conference from 17 – 19 November 2021 to witness the largest event MTAA has ever delivered. Despite the challenges faced from Government restrictions imposed because of the pandemic, the event broadcast a successful 3-day program featuring key leaders and influencers across the industry, government and academia to discuss the issues affecting MedTech.

Twenty-three sessions were covered with over forty presenters sharing their knowledge and insights covering themes on politics, Prostheses List, health

technology assessment, regulatory issues and many more. Day one opened with a political session featuring the newly formed Parliamentary Friends of MedTech panellists Milton Dick MP and Dr Katie Allen MP. They were joined by Senator Perin Davey presenting their views on the upcoming federal election and the dynamic operating environment ahead for the industry. The remainder of the day continued with on Prostheses List discussions on reform overview and updates, benefit review processes and methodology, and scope & rewards. The discussions featured appearances from consumer and patient groups, private hospitals, AOA, IHPA, MedTech policy professionals and the Department.



286
INDIVIDUALS LOGGED
INTO THE THE
MEDTECH22 VIRTUAL
CONFERENCE

Day two kicked off with the role of the patient voice in health technology assessment followed by concurrent sessions from John Skerri's TGA update and a media update on the changing policy and policy environment. Further discussions continued throughout the day with sessions on digital health with emphasis on increased EQ and IQ, the importance of clinical trials in Australia, value-based procurement, benefits of workplace diversity and an update from MedTech Europe wrapped up the remaining sessions for the day.

Day three continued with FDA opening on their update into the US regulatory landscape, followed by

an intriguing group discussion on the importance of advocacy work featuring a variety of MTAA members. Building a cyber community to protect healthcare drew in a large crowd as well as the session on navigating the journey of product commercialisation from R&D to deployment. MTAA Chair, Maurice Ben-Mayor wrapped up the event, signing off on the challenges we face as an industry during uncertain times and congratulated industry for rising up to the occasion of keeping Australia safe and healthy. This formed a neat segue into the Australia MedTech Industry Awards which followed.

Australian MedTech Industry Awards

17 November 2021

Once again, the Australian MedTech Industry Awards brought together industry leaders to celebrate and pay tribute to a year of innovation and leadership. Held at the end of day three of the MedTech21 Conference, MTAA was proud to announce the winners in five award categories. Winners were chosen from a record number of high-quality entries, a testament to an industry that is developing and providing the Australian healthcare system with innovative solutions for patients.

The Kerrin Rennie Award was established in 2007 to recognise and profile the innovation and extraordinary contribution of medical technology in improving health outcomes of patients. This year's award was won by Canon Medical for their Hi-Def Detector, the world's first high-definition flat panel detector used in image guided endovascular procedures. Ricky Davidson, Canon Medical ANZ Manager of X-Ray and Angiography, accepted the award sharing their gratitude to the recognition received by his peers.

The Outstanding Achievement Award is open to individuals who have contributed in a significant way to the development of the medical technology industry through improvement to patient outcomes or excellence in leadership and innovation. This year's winner, Warren Bingham, was recognised for his role in improving the lives of thousands of people, expanding clinical practices for hundreds of gastroenterologists to improve the health outcomes of their patients. In 2000, Warren introduced PillCam in Australia and New Zealand. Working with some of Australia's leading and emerging gastroenterologists and the craft profession GESA, Warren compiled a large health economic study in Australia and through the strength of the evidence, was successful in establishing Capsule Endoscopy on the Australian Medicare Benefits Scheme. By 2004, Australia had become a world leader in clinical adoption of Capsule Endoscopy. Warren's passion to empower people and save lives, combined with more

than 30 years of proven success in the medical devices sector, made him a clear choice as this year's winner of the Outstanding Achievement Award.

Women in MedTech is a Board-led initiative which started in July 2015 in response to the gap of women in leadership positions across the industry. The support and engagement on this issue from members of our industry has been overwhelming, making it a clear issue of importance for MTAA to support. The Women in MedTech Champion is awarded to an individual or a company who has contributed to advancing the mission and goals of Women in MedTech Committee. This year's Champion was Emma Press. Emma is the Senior Director of Ethics & Compliance APAC and Legal & Compliance ANZ at Medtronic Australasia. She is a passionate leader and advocate for inclusion, diversity, ethics and equity. Her work as an executive sponsor for the Medtronic ANZ's Women's Network and her role in many company initiatives, events and education programs delivered throughout her sponsorship earned strong recognition from her peers. Emma led numerous initiatives to build an inclusive culture within Medtronic where women feel empowered to speak up, such as 'Fearless Females', 'Empower Your Voice', Inclusive Culture workshops and Global Legal & Compliance Inclusion Workstream. Emma has also been a mentor as part of the Advance Women Scientists in Aboriginal Health and has championed the 'Yes-Flex' program supporting the Diversity Council of Australia (DCA) membership.

The Women in MedTech Company Champion was awarded to Baxter Healthcare again in 2021. Named as the top healthcare company for gender equality by the Workplace Gender Equality Agency, Baxter Healthcare now holds a citation for 11 years as an 'Employer of Choice for Gender Equality'. Their roadmap to detailed gender equality, inclusion and diversity in Australia implemented several new training programs and policies to strengthen equitable participation



in career development and inclusive workshops. In the last 18 months, Baxter has taken active steps to raise awareness of and address the increased risk of domestic violence and loss of income women face. These steps include access to counselling services, promotion of the company's Domestic Violence Leave policy and maintaining a policy of an "Open and Safe Workplace" for employees to work from if they were unable to safely work from home. Furthermore, new policies are in place such as flexible working arrangements, Parental Leave for women and men, Breastfeeding Policy, and paid superannuation for employees on parental leave. These have helped to grow industry through diversity and gender equality.

The WiMT Emerging Women in Leadership Award recognises an exceptional female leader who has taken on a career challenge, move or change, exhibited leadership qualities and has moved the

industry forward. This year, Fiona Lim from Medtronic was awarded the winner. After making a significant change from the FMCG industry, Fiona forged a successful career in IT across Asia and Australia before commencing her career at Medtronic from June 2019. Fiona made a considerable impact early in the organisation where she utilised her talent to improve and inspire the ANZ executive leadership team, ANZ culture and bring innovative solutions to many within Medtronic. Her role expanded a year later to IT Director for APAC Commercial Excellence, is responsible for several key portfolios. Balancing her new role, she also devotes time and energy to Women in IT community group where she is the global co-chair, and mentors students from Women's College at the University of Sydney. Fiona's progression is a true success story and makes for a very worthy winner of this year's award.

MARCH 2022



Regulatory Affairs for Medical Devices Workshop

17 March 2022

In an MTAA first, a Regulatory Affairs for Medical Devices Workshop opened its doors to MedTech professionals with an interactive workshop to provide detailed coverage of the medical device regulations in Australia. Co-hosted with TGA, this sold-out event addressed common scenarios faced by regulatory professionals, providing guidance and clarity.

EU MDR Update with MedTech Europe

21 March 2022

MedTech professionals were treated to a rare opportunity to sit down with MedTech Europe's Oliver Bisazza, Director of Regulatory Policy, to hear an update on European Medical Device Regulation (EU-MDR). Co-hosted by MTAA and Hogan Lovells, the event provided an overview of the current EU MDR market and the potential impacts on Australian manufacturers and sponsors.

APRIL



Regulatory Members-Only Networking Event 28 April 2022

MTAA hosted its first members-only networking event for industry professionals in the regulatory space. Located in the new MTAA office in Macquarie Park, this event brought together like-minded individuals to strengthen their business connections, share advice and insights, and open opportunities for support.



MAY



MTAA Workshop | Advertising and Promotion of Medical Devices and Effective Communication Session

19 May 2022

MTAA and Hogan Lovells hosted a members-only post-market workshop on the compliance of advertising laws for medical devices and how to best communicate with TGA. The sold-out event firstly examined the new Therapeutic Goods Advertising Code (TGAC) and how Australian Consumer Law (ACL) relates to medical device advertising.

Part two took a more practical approach, going through what information should be provided for TGA, when it should be presented, and how much information is enough.

JUNE



Regulatory Networking Event 23 June 2022

Forty-two regulatory professionals gathered in the Macquarie Park office to join the second Regulatory Networking Event of the year with a new format in place.

Part One opened with a conversation with guest speakers Leanne Etherington of Device Technologies, Chair of the MTAA Regulatory Affairs Forum, and Mahesh Datar of Medtronic, Chair of the MTAA Regulatory Affairs Committee. Both speakers shared their story of working with the biggest MedTech brands in the country and their journey navigating the challenges in the regulatory sector.

Part Two of the conversation continued the discussion with Q&As and a networking session.



TRAINING BY NUMBERS

IN THE LAST 12 MONTHS



5,807

INDIVIDUALS COMPLETED
MTAA TRAINING



3,712

INDIVIDUALS COMPLETED
THE CODE OF PRACTICE
TRAINING



1,330

INDIVIDUALS COMPLETED
THE OPERATING
THEATRE PROTOCOLS
COURSE



165

INDIVIDUALS COMPLETED
THE OTP VIRTUAL
TRAINING COURSE



Professional Development

Professional development is essential for healthcare professionals to stay up to date with the latest standards, reduce risk and build better practices in the healthcare environment.

MTAA introduced the new training platform ChalkPort – an upgraded training platform offering increased concurrent user capacity and greater interactions for students. The platform successfully hosted the updated Operating Theatre Protocols courses and later the new Code of Practice training, which was completed by 3,712 individuals. The Code of Practice training course is essential learning for MTAA members In-house technicians and healthcare professionals in areas of marketing, sales, customer service, regulatory and legal.

The Compliance and Competition Training Course was updated, complying with Australian Competition and Consumer Commission guidelines. This updated course is available online and free of charge for committee members.

The face-to-face Introduction to Operating Theatre Protocols program was changed to a virtual classroom program to accommodate COVID-19 restrictions. This was completed by 165 individuals through our virtual training platform with a live instructor, scenarios, active discussions and video handwashing techniques.

This is a total of 5807 individuals who participated in MTAA training courses, representing a 67% increase on the previous year.

Women in MedTech

The Women in MedTech (WiMT) Committee continued to promote the WiMT initiative to the MedTech industry. Their mission has continued for many years to proactively promote gender diversity within the MedTech industry, and effectively support women to unlock their full potential.

This year saw several new members join the committee with sixteen members of different genders, roles and member organisations committing to the cause.

Events and social media continued to be the driving force for the conversation. Highlights for the year included celebrating International Women's Day, A Virtual Coffee Catch with Up- Glow up Careers, the webinar on Understanding your Mental Fitness in conjunction with R U OK Day and the relaunch of the Mentoring Program in May 2022.

Mentoring Program

The MTAA Mentoring Program is a Women in MedTech initiative. It aims to facilitate relationships between experienced mentors, who can share advice, knowledge and experience with female mentees to assist in their professional and career development within the MedTech industry. The goal is to assist more women in their career progression into management and senior management positions within the MedTech industry as well as resulting in a mutual professional development relationship.

The Mentoring Program entered its second year from June 2022 with a greater number of applicants than its pilot year in 2019. This year's program partnered

25 mentor and mentees from 11 companies with a successful pairing of young female mentees with mentors. MTAA managed the program internally and reports its activities directly to the Women in MedTech committee.

Sexual Harassment Project

MTAA engaged Bespoke Consulting and Communications to investigate the prevalence of sexual misconduct experienced by customer-facing staff from healthcare organisations and their customers. The investigation developed policy recommendations to address any issues by asking all client-facing staff of MTAA member organisations to respond to a survey about their experience of sexual misconduct by customers. The survey received an above average response rate for a survey of this nature. Staff reported experiencing sexual misconduct from customers over their time in the industry at considerably lower rates than the national average. After the results of the survey were analysed, a set of draft policy recommendations were presented to the MTAA Board and then workshopped and refined with customer-facing staff over a series of online roundtables.

The process will assist member companies to provide, either directly or through the MTAA, an anonymous complaints service for those who have experienced sexual misconduct from a customer. The anonymous procedures will be standard across all member companies and collected quarterly by the Association. MTAA will finalise the relevant procedures for supporting companies to communicate options for assistance to staff.

WORKING WITH INDUSTRY COLLABORATION

Working to unite the industry and engage a broader range of stakeholders is a way to strongly articulate and demonstrate the value proposition of the medical technology industry to the Australian community. Collaboration strengthens MTAA itself in terms of leadership, representation and advocacy, as well as membership.

CTC-M Program

MTAA is supporting MTPConnect, one of the Commonwealth Government's five industry growth centres, with the delivery of the Clinical Translation and Commercialisation - MedTech (CTCM) program, a \$19.75 million initiative funded by the Australian Government's Medical Research Future Fund (MRFF). The CTC-M program seeks to identify and nurture high-quality medical device projects with strong commercial potential under development by start-ups and small-to-medium enterprises.

MTAA played a vital role to support MTPConnect and other program delivery partners, including Sydney's Cicada Innovations and Adelaide's Medical Device Partnering Program, to screen Expressions of Interest and coach shortlisted applicants to prepare their final submission for Investment Committee review. Close to 70 Expressions of Interest were received in the first round, which were shortlisted down to 36 candidates for detailed review and coaching sessions, led in groups of twelve by each of the partners. A further shortlist of 11 applicants were invited to submit a final proposal for investment committee review. This process will be repeated for Round Two, commencing September 2022. MTAA's second role is to work with its members to provide active coaching and guidance for the successful awardees over a two-year period.

Australian Ethical Health Alliance

MTAA is a founding member of the Australian Ethical Health Alliance (AEHA). The Alliance aims to improve healthcare in Australia through articulation and affirmation of ethical principles that promote the interests of patients and consumers, enhance access to safe and effective healthcare, encourage ethical collaboration in the healthcare sector and build public trust. MTAA is working with 71 other health sector organisations to achieve these aims.

Australian Breast Device Registry

MTAA membership of the Steering Committee of Australian Breast Device Registry (ABDR) ensures affected members' interests are considered and that industry matters are considered in the development of policy at the national level. MTAA continues to support this committee regularly.

APACMed

MTAA and APACMed directly engage on various issues across the two associations - such as reimbursement, regulatory, digital health and events. In addition, over the last 1-2 years, APACMed has significantly enhanced its engagement with all country associations.

BioMedTech Horizons Program

MTAA is supporting MTPConnect to deliver the BioMedTech Horizons program (BMTH), a \$45 million Medical Research Future Fund (MRFF) initiative. The program will support innovative, collaborative health technologies, drive discoveries towards proof-of-concept and commercialisation that address key health challenges as well as maximise entrepreneurship and idea potential. The BMTH has now extended to its fourth round, with five highly promising medical technology projects across Australia collectively receiving funding of \$4 million in September 2021.

The Round Four recipients included:

- Aria Research Pty Ltd (NSW) \$800,000 – Developing a non-invasive bionic vision wearable development prototype for the blind and vision impaired
- ResusRight Pty Ltd (NSW) \$800,000 – Development of the 'Juno', a novel ventilation monitoring system for neonatal resuscitation
- Seer Medical (VIC) \$800,000 – Developing 'Sense Cardiac', a cloud-enabled wearable cardiac monitor for at-home use
- VitalTrace Pty Ltd (WA) \$800,000 – Development of a precision real-time foetal biosensor for the prevention of stillbirth and foetal complications during childbirth
- 3DMorphic Pty Ltd (NSW) \$800,000 – Personalised spinal surgery for Australians; a clinical trial of 3DMorphic's advanced manufactured patient-specific spinal fusion devices.

In May 2022, MTPConnect announced nearly \$900,000 in Round Four funding for three important medical technology projects in Victoria and Western Australia. These three projects are:

- Atmo Biosciences Pty Ltd (VIC) \$343,310 – Further development of the 'Atmo Gas Capsule' through clinical trials for better diagnosis and treatment of gastrointestinal disorders. The company was also awarded funding in Round Three of the BMTH program.
- Cortical Dynamics Ltd (WA) \$137,000 – Further development of the 'Brain Anaesthesia Response Monitor' (BARM) to optimise patient experience under anaesthesia and to implement brain data monitoring and feedback.
- Proteomics International (ASX: PIQ) (WA) \$413,516 – Further development of the patented PromarkerD test, which predicts diabetic kidney disease (DKD), and establishing an onshore manufacturing capability.





CODE OF PRACTICE INTEGRITY

During the 2021-2022 financial year the Code Authority (CA) successfully sought the Board's approval to reinstate the temporary exemption of members from clause 9.9.4 of the Code of Practice Edition 11 (the Code) to satisfy the increased need to support hospitals and other healthcare settings (Healthcare Professionals [HCPs]) to ensure they have adequate supplies to be able to care for and treat patients in a healthy and safe environment during the COVID-19 pandemic. This exemption was cancelled in June 2022 when it was recognised the exemption was no longer required.

The CA also proposed amendments to the Code to include compliance with the Vendor Credentialing Standard AS 5182:2018 (VC Standard), which was ratified by members during the 2021 Annual General Meeting (AGM). The Code of Practice Edition 12 came into effect from 1 January 2022. During the first six months of

monitoring in 2022, the Code Monitoring committee monitored member compliance with the VC Standard, and 14 members have been issued letters of VC Certification. Many members are in the follow-up phase and the committee expect all reports to be finalised and closed by the end of 2022. A monitoring report from each member during 2021 was received, finalised, and closed by the end of the year. During the 2021-2022 financial year there were no complaints received.

A Code Review Working Group (CRWG) was formed with a purpose to oversee the substantial Code Review which began in March 2022. The initial consultation with key stakeholders was finalised mid-May and the CRWG worked on the draft Code following a review of the submissions received. It is expected the draft Code will be ready for members to vote on at the AGM in 2022.

2,224 INDIVIDUALS
COMPLETED THE CODE OF
PRACTICE TRAINING IN 2021-22
BRINGING A TOTAL OF 3,712 COMPLETIONS
SINCE ITS LAUNCH TWO YEARS AGO.



MEMBERSHIP

INDUSTRY & ASSOCIATE

115 MEMBERS
 86 Industry Members
 29 Associate Members

Industry Members

3D-Matrix Medical Technology Pty Ltd
 3DMEDiTech Pty Ltd
 3DMorphic Pty Ltd
 3M Australia Pty Ltd
 Abbott Medical Australia Pty Ltd
 Abbott Medical Australia Pty Ltd Abbott Vascular
 Alcon Laboratories (Australia) Pty Ltd
 Allergan Australia Pty Ltd
 AlphaXRT Ltd
 Analytica Ltd
 APNE Surgical Pty Ltd
 Arthrex Australia Pty Ltd
 Atomo Diagnostics Ltd
 Australasian Medical & Scientific Ltd
 Avanos Medical Australia Pty Ltd
 B Braun Australia Pty Ltd
 Bard Australia Pty Ltd
 Bausch & Lomb Pty Ltd
 Baxter Healthcare Pty Ltd
 Bioclect Pty Ltd
 Bionic Air Pty Ltd
 Biotronik Australia Pty Ltd
 Boston Scientific Pty Ltd
 Brainlab Australia Pty Ltd
 BTC health
 Cardinal Health Australia 503 Pty Ltd
 ConMed Australia Pty Ltd
 Cook Australia Pty Ltd
 Corin (Australia) Pty Ltd

Industry Members

Cortical Dynamics Limited
 Device Technologies Australia Pty Ltd
 DJO Global Pty Ltd
 Edwards Lifesciences Pty Ltd
 Elekta Pty Ltd
 Evolution Surgical Pty Ltd
 Exactech Australia Pty Ltd
 Fresenius Kabi Australia Pty Ltd
 Fresenius Medical Care Australia Pty Ltd
 Gamma Gurus Pty Ltd
 Gel Works Pty Ltd
 Getz Healthcare
 Grey Innovation Pty Ltd
 Hemideina
 Heraeus Medical Australia Pty Limited
 Hologic (Australia & New Zealand) Pty Ltd
 Horten Medical Pty Ltd
 Hospital Products Australia
 Hydrix Services Pty Ltd
 Integra Lifesciences Pty Ltd
 InterMed Medical Pty Ltd
 Johnson & Johnson Medical Pty Ltd
 KLS Martin Australia Pty Ltd
 Laminar Air Flow Pty Ltd
 LifeHealthcare Pty Ltd
 Lima Orthopaedics Australia Pty Ltd
 LivaNova Australia Pty Ltd
 Materialise Australia Pty Ltd
 MatOrtho Pty Ltd

Member Focus

Total membership numbers have held steady this year with 115 members, this includes 86 corporate members and 29 associate members. This year we welcomed 5 new members including: Integra Lifesciences, Heraeus Medical Australia, Lima Orthopaedics Australia, Hydrix Services and MatOrtho. We also welcomed 2 new associate members this year: Commercial Eyes and OneMD.

Industry Members

Medacta Australia Pty Ltd
 MED-EL Implant Systems Australasia Pty Ltd
 Medical Specialties Australasia Pty Ltd
 Medigroup Australia Pty Ltd
 Medistar
 Medtronic Australasia Pty Ltd
 MicroPort CRM Pty Ltd
 Molnlycke Health Care Pty Ltd
 Nevro Medical Pty Ltd
 NL-Tech
 NuVasive (AUST/NZ) Pty Ltd
 Olympus Australia Pty Ltd
 Palette Life Sciences Australia Pty Ltd
 Paragon Therapeutic Technologies Pty Ltd
 Prism Surgical Designs Pty Ltd
 Roche Diabetes Care Australia Pty Limited
 Singular Health Pty Ltd
 Smith & Nephew Pty Ltd
 Smiths Medical Australasia Pty Ltd
 Spectrum Surgical Pty Ltd
 Stryker Australia Pty Ltd
 Teleflex Medical Australia Pty Ltd
 Terumo Australia Pty Ltd
 Tunstall Australasia Pty Ltd
 Varian Medical Systems Australasia Pty Ltd
 Vitalcare Pty Limited
 W L Gore & Associates (Australia) Pty Ltd
 Zimmer Biomet Pty Ltd

Associate Members

Alessandra Doolan
 Avania Pty Ltd
 Cancer Care Associates Pty Ltd
 Circuitwise Electronics Manufacturing
 Clinical Research Corporation Pty Ltd
 Commercial Eyes Pty Ltd
 DHL Supply Chain (Australia) Pty Ltd
 Genesis Care Pty Ltd
 George Faithfull Advisory Pty Ltd
 Healthcare Professionals Group
 Hogan Lovells Australia
 ICON Cancer Care
 IDE Group
 Illuminate Health Consulting Pty Ltd
 JEM Med
 Labcorp Development Pty Ltd
 Lucid Health Consulting Pty Ltd
 Mainfreight Distribution Pty Ltd
 Medihost Solutions Pty Ltd
 Medtechnique
 MTP Connect (Affiliate)
 NSW Smart Sensing Network
 OneMD Pty Ltd
 Pagero Australia Pty Ltd
 Pettit Pharma & Device Pty Ltd
 PharmaLex
 Prospitalia h-Trak Pty Ltd
 Regulatory Concepts Pty Ltd
 Smartways Logistics

BOARD OF DIRECTORS



MAURICE BEN-MAYOR

CHAIR
PRESIDENT
STRYKER SOUTH PACIFIC

B.Sc (UNSW), Exec MBA (AGSM)

Maurice has over 20 years of experience in the Medical Technology industry across senior roles in sales, management, marketing and market access. Maurice has been at Stryker for 18 years and is currently the President of the ANZ Business.

Maurice joined the board in December 2016 and was elected Chair in November 2018, and re-elected in November 2019, November 2020 and November 2021.



SUSAN MARTIN

VICE-CHAIR
MANAGING DIRECTOR, JOHNSON & JOHNSON MEDICAL DEVICES ANZ

Monash University, Bachelor of Nursing, GAICD.

Susan started her career as a critical care nurse and has spent two decades working in the medical device sector. Throughout her career she has taken increasingly senior local, regional and global commercial and people leadership roles culminating in her current appointment as Managing Director of Johnson & Johnson Medical Devices (JJMD) for Australia and New Zealand in January 2018. Before being appointed Managing Director, she was most recently the Asia Pacific Franchise Lead for JJMD's Cardiovascular Specialty Solutions business and responsible for providing leadership to drive the business's global franchise strategy and pipeline.

Susan joined the board in November 2018 and was re-elected in November 2020.



REBECCA CORTIULA

SENIOR MANAGING DIRECTOR,
VARIAN MEDICAL SYSTEMS,
AUSTRALASIA

B.Sc (UTS), MBA (AGSM), GAICD

Rebecca has been working within the Australian Healthcare system for more than 20 years. Prior to leading the Varian ANZ team, she was the Managing Director of Terumo Corporation ANZ. She worked within the Australian hospital system as a Hospital Scientist as well as working for the Australian Red Cross Blood Service. Rebecca is passionate about healthcare and ensuring that Australia has a sustainable healthcare system that can be readily accessed by all. She is also a strong advocate of supporting women to aspire to senior organisational roles and is the Chair of the Women in MedTech Committee.

Rebecca joined the board in November 2015, was elected Vice-Chair in December 2016, resigned in October 2019, joined the Board in March 2020 and was elected in November 2020.



MATTHEW MUSCIO

CHIEF EXECUTIVE OFFICER,
EBOS MEDICAL TECHNOLOGY

Queensland University of Technology, Bachelor of Business (International Business). Melbourne Business School, Post Graduate Degree in Management.

Matt has 21 years' experience in the medical device industry across sales, marketing, operations and management functions for private, multinational and ASX-listed entities. Currently Chief Executive Officer of LifeHealthcare, Matt has led the organisation through significant growth, expanding the therapeutic specialities serviced by their medical technology distribution business and entering into local technology development with the recent investment in Australian Biotechnologies.

Matt joined the board of the MTAA in November 2017 and was re-elected in November 2021.



PATRICK WILLIAMS

VICE PRESIDENT, ANZ & KOREA,
EDWARDS LIFESCIENCES

Master of Business (UTS)

Being in the medical device industry for more than 32 years now, Pat started his career at Medtronic where he held several roles including Territory Management, Sales Management, Marketing and General Management. Pat proudly joined Edwards Lifesciences in 2011 where he initially started his career as the Business Unit Manager of Critical Care. In April 2013, Pat was then appointed as the Managing Director of the Australia and New Zealand Business and in 2020 he also assumed responsibility for Korea.

Pat joined the Board in October 2019 and was re-elected in November 2021.



ELIZABETH CARNABUCI

VP AND MANAGING DIRECTOR ANZ | VP
DIABETES APAC, MEDTRONIC AUSTRALASIA

Bachelor of Commerce (UNSW Sydney), MBA (MGSM), GAICD

Liz joined Medtronic in November 2019 as VP, Diabetes Group APAC. In May 2020, Liz added VP & MD Australasia to her remit. Medtronic offers technologies and solutions to treat a wide range of medical conditions. Liz is an experienced and strategic commercial leader with more than 25 years of sales and marketing experience in the healthcare industry. Liz holds a Bachelor of Commerce degree from UNSW Sydney as well as an MBA from Macquarie Graduate School of Management in Australia, and Graduate Diploma AICD. She is currently pursuing a Bachelor of Psychology at the University of Central Queensland.

Liz joined the board in August 2020, resigned in November 2020, was appointed in December 2020 and elected in November 2021.

BOARD OF DIRECTORS



CHRIS SZELECZY

GENERAL MANAGER – SERVICE AND OPERATIONS, OLYMPUS AUSTRALIA

Master Commerce – Strategic Management (Honours)

Chris has over 15 years of experience within the Medical Technology industry in several leadership roles across operations, service, commercial operation, corporate accounts and general management throughout Australia, New Zealand and Asia Pacific. Chris’ previous experience within the MedTech sector has been with Stryker, ConMed and the MTAA and he is currently the General Manager - Service and Operations at Olympus.

Chris joined the board in October 2019 and was re-elected in November 2021.



WARREN BALLINGER

PRESIDENT, AUSTRALIA & NEW ZEALAND, ZIMMER BIOMET

Bachelor of Economics (Accounting Major) Macquarie University, ICAA

With 20 years’ experience within the orthopaedic device industry with a variety of connections from International, Regional and within Australia & New Zealand.

The experience of leading two major Orthopaedic companies, being Biomet and now Zimmer Biomet, I have been successfully involved and exposed to government price negotiations on various formats since 2001. Recently holding the position as the Chair of the Orthopaedic Sub Committee Forum with the MTAA.

Warren joined the board in November 2020.



LYN DAVIES

MANAGING DIRECTOR, TUNSTALL AUSTRALASIA

Dip Bus Mgt, PERSA, AMACs, MAICD

Lyn commenced with Tunstall in October 2004. A seasoned executive with over 25 years in senior leadership roles across the private and public sectors. Prior to Tunstall, Lyn has worked with well-known organisations such as Logan City Council, Mater Hospitals QLD and CITEC Queensland State Government. Lyn has presented both nationally and internationally on assistive technology and Connected Healthcare solutions and is experienced in the implementation and building of 24/7 operations centres within Australia and parts of the Asia Pacific regions.

Lyn joined the Board in December 2013, retired in October 2019, was appointed in May 2021.



JEFF SOO

MANAGING DIRECTOR, TERUMO AUSTRALIA

Masters of Business Administration - AGSM, Bachelor of Communications - University of Canberra

With 18 years of medical device industry experience in ANZ and APAC, Jeff brings skills in general management, strategic planning and execution, and experience in sales and marketing gained from leading Australian med-tech and US-based MNCs. He has a passion for the benefits of medical technology and working with members of an industry responsible for facilitating their availability to improve health outcomes for all Australians. Jeff has experience across ENT, cardiology, radiology, cardiac surgery, endovascular, TAVR, and medical consumables gained locally and abroad working in small companies to among the largest in the world.

Jeff joined the Board in November 2021.



FORMER BOARD MEMBER

STEVE FLYNN	HEATH PRIESTLY	MARIUS FOURIE
SVP & PRESIDENT, ASIA PACIFIC, BAXTER HEALTHCARE	DIRECTOR OF SALES & MARKETING, DEVICE TECHNOLOGIES	GENERAL MANAGER AND MANAGING DIRECTOR, ABBOTT MEDICAL, ANZ
<p>Steven has responsibility of over 1,100 employees and oversees a significant commercial, manufacturing and compounding pharmacy footprint across Australia and New Zealand. As the current Vice Chair of the MTAA board, Steven has ensured that Baxter is active in advocating directly for MTAA policy platform to deliver benefits to the entire membership. Since 2006, Steven has held senior executive roles in Baxter Australia, New Zealand and Asia Pacific. Prior to joining Baxter Healthcare, Steven worked at TNT and GM Holden Limited.</p> <p>Steven joined the board in November 2015, was elected Vice-Chair in November 2017, elected in November 2020, and retired from November 2021.</p>	<p>Heath has over 25 years of experience in the allied health and medical device industries. During this time he has gained a great depth of understanding, across the industry, working with a large variety of medical device companies, both locally and in international markets.</p> <p>He has a particular focus on the ASEAN region and is currently the Director of Sales and Marketing for Device Technologies, with responsibility for the territories of Australia, New Zealand and South East Asia. He has broad clinical experience having spent many years working actively in the hospital setting alongside clinicians and hospital administrators. He has particular expertise across the surgical specialties of Laparoscopic and Robotic Surgery and Orthopaedics.</p> <p>Heath joined the board in November 2020 and resigned from May 2022.</p>	<p><i>MBA – Herriot-Watt University Edinburgh, B Commerce, Marketing - University of Pretoria, South Africa, MAICD.</i></p> <p>Marius is an experienced commercial leader with an established track record in the healthcare and medical device industry with a career spanning more than 25 years across Africa, Australia, New Zealand, Asia, the Middle East and Eastern Europe. He has worked with talented teams across various geographies, cultures and healthcare markets on technology that impacts those who trust us with their health every day, enabling them to live their fullest lives.</p> <p>Marius joined the board in June 2020, elected in November 2020, and resigned from June 2022.</p>

WORKING WITH MEMBERS COMMITTEES

Active participation of members is essential to MTAA achieving success. This year saw more than 220 member representatives contribute to the work of MTAA committees, forums and working groups. MTAA forums and alliances have progressed key initiatives relevant to participating members.

Public Affairs Committee

The Public Affairs Committee (PAC) provides oversight of the Reimbursement, Regulatory and Industry Policy Committees, ensuring a coordinated and aligned strategy and communications approach to MTAA’s activities. The PAC sets the advocacy direction for the MedTech industry, identifying and engaging with relevant stakeholders in healthcare policy decision making.

One of the PAC’s objectives over the past year has been to develop and implement an advocacy program that includes active stakeholder engagement to promote MTAA’s policy positions on the strategic issues identified by MTAA’s subcommittees. The PAC also holds responsibility for overseeing the implementation and content of the Digital Advocacy Platform.

Regulatory Affairs Committee

The Regulatory Affairs Committee (RAC) is responsible for supporting the strategic development and delivery of MTAA’s regulatory policy priorities. The RAC is also the body that discusses the operational issues facing the association’s members in their interactions with the Therapeutic Goods Administration (TGA) in meeting the regulatory requirements for supplying MedTech in Australia.

- The RAC’s other objectives are to develop regulatory focused strategic initiatives for the MTAA including:
- Reviewing the effectiveness of the regulatory system for MedTech in Australia,
 - Contributing to MTAA’s involvement with international regulatory organisations,
 - Liaising with Commonwealth departments and industry associations in Australia and overseas, and
 - Providing advice on the professional development of regulatory staff in the medical technology sector.



WORKING WITH MEMBERS

COMMITTEES

Reimbursement Committee

The Committee met eight times during the 2021-22 Financial Year as well as having multiple working group meetings on specific topics. Members were well represented in FY22 and the Committee received many new nominations at the end of 2022, not all of which could be accommodated. Michael Simmonds (Boston Scientific) continued to chair the Committee.

The focus of the Committee was strongly on Prostheses List (PL) reform, being the main engine of policy work to provide advice to the Board and inform MTAA responses to the Department. This included responses to the five formal consultations in FY22 and preparatory work for other key issues. Some Committee members participated in PL listing workshops run by the Department.

The Committee discussed the performance of the Department and committees in assessing PL listing applications to inform MTAA's advice to the Department.

The Committee also aims to focus on issues beyond the PL and during the year provided feedback on issues including the Independent Hospital Pricing Authority New Technology Framework, Medical Benefits Schedule (MBS) reviews and the proposed Health Technology Assessment (HTA) Review.

Finance

The Finance Committee assists the Board in the effective discharge of its responsibilities for financial reporting, internal controls, audit, compliance and risk management.

Industry Policy Committee

The role of the Industry Policy Committee (IPC) is to promote initiatives (outside regulatory and reimbursement) which impact on industry development and sustainability and healthcare policy.

The Committee is responsible for developing policy positions and engaging with stakeholders on the digital healthcare agenda (including cybersecurity), the electronic patient record, mobile healthcare and registries. It is also responsible for supply chain issues, including traceability of medical devices, and regularly engages with GS1 Australia.

MTPConnect initiatives, R&D, clinical trials and commercialisation all fall within the Committee's purview. Industry Policy Committee meetings are used to monitor the implementation of the \$30 million grant for SMEs under the MTAA-Government Agreement.

Code Authority

The Code Authority Committee reports to the Board and reviews Code Complaints, issues, and provides direction to the Code Monitoring Committee. The Committee consists of an independent Chair, two Board representatives, a healthcare professional, a medical industry representative, a consumer representative, and six industry representatives.

Code Monitoring

The Code Monitoring Committee reports to the Code Authority Committee and reviews the monitoring reports submitted by MTAA members on a pre-determined section of the Code of Practice (the Code). Where appropriate, the Committee refers issues to the Code Authority for further consideration. The Code Monitoring Committee consists of an independent Chair, a healthcare professional, an academic professional and six industry representatives.

MedTech Conference

This committee drive the agenda, sponsorship and attendance of the Annual Conference to ensure it appeals to MedTech industry leaders and executives. In 2021, 286 influencers and leaders logged in to witness the MTAA Annual Conference hosted in a virtual environment.

Women in MedTech

The Women in MedTech Committee was established to drive and fulfil several objectives, including to continue to promote the WiMT initiative to the wider MedTech industry. Despite challenges in the workforce due to the pandemic, MTAA organised a number of WiMT initiatives as part of its objective to raise the profile and benefit of women within the MedTech industry through their mentoring program, targeted campaigns and events.



WORKING WITH MEMBERS

FORUMS

Cardiac Forum

The Cardiac Forum is made up of the five MTAA members who distribute cardiac implantable electronic devices (CIEDs) in Australia. The Forum met weekly during FY22 to focus closely on how the extensive technical services provided by the CIED companies to patients and clinicians in the private sector would continue to be funded following the Prostheses List (PL) reform Budget announcement. The Budget announcement did not include any provision to pay for the cardiac services and the Forum was able to work with MTAA to achieve agreement on a process to agree on future payment for the services with a deferral of all benefit reductions on CIEDs until 1 July 2023. This included ongoing engagement with clinicians including a signed letter of support, and alignment with a key consumer group. The issue is ongoing.

Regulatory Forum

The Regulatory Affairs Forum is an extension of the Regulatory Affairs Committee (member base is large and covers a range of members) and acts as an information-sharing space to ensure the broad membership is covered and issues are passed up to the committee and subsequently to the TGA and RegTech Committee.

Neuromodulation Forum

The Neuromodulation Forum operated for its first full year with all six distributors of neuromodulation devices in pain and epilepsy participating in the Forum. The Forum was very active, meeting on 10 occasions. Topics included engaging with the Neurostimulation Society of Australia and New Zealand, responding to media and inquiries into neuromodulation devices, as well as Prostheses List reform issues.

SME Forum

The SME Forum was formed to address the major issues affecting or hindering SME members doing business. Their top priorities include tendering, impact of PL cuts on SMEs, complying with ESG requirements as part of procurement processes and other reimbursement issues including changes to the Medicare Benefits Scheme. The Forum is designed to relieve these pain points and address other common interests for SME Member companies.

Ophthalmic Forum

The Ophthalmic Forum (OF) is an independent working group of companies that produce and/or distribute intraocular lenses (IOLs) which are listed on the Prostheses List. While these companies make products used in eye health in the public sector, there are differences in the product options. The OF consists of MTAA members and non-member companies to ensure broad stakeholder engagement in understanding industry policy issues. The OF meets monthly to discuss and progress policy positions, PL Reform, and advocacy for ocular health.

Clinical Investigations Forum

The Clinical Investigations Forum (CIF) aims to establish the value of MedTech clinical trials for the industry, work with Government on their various initiatives to shape the Clinical Trials space in Australia to ensure Australia becomes a preferred location to conduct Clinical Trials, and to establish the CIF as the body of experts in MTAA to cover this topic.

The CIF worked with a representative from the Office for Health and Medical Research to ensure the national Clinical Investigation Research Agreement (CIRA) templates were updated and approved by the South-Eastern Border States Committee, the updated templates of which are available on the MTAA website.

The CIF was invited to provide input during the first phase of consultations held by the Australian Commission on Safety and Quality in Healthcare (the Commission) on the development of the One-Stop-Shop. Since September 2021 and during the second phase of consultations, the CIF was given a demonstration and opportunity to test the Proof of Concept developed by the Commission. The Proof of Concept is not a final platform, but a high-level prototype with a subset of functions for demonstration and testing.

Orthopaedic Forum

The MTAA Orthopaedic Forum provides MTAA orthopaedic members with the opportunity to discuss and address issues of mutual interest and concern to MTAA member companies involved in the orthopaedic sector. The Forum provides collective linkages to the Australian Orthopaedic Association in circumstances where an industry response is more appropriate. The output of the MTAA Orthopaedic Forum also informs relevant MTAA committees and the MTAA Secretariat with aggregated input on key industry policy matters. The orthopaedic sector has continued to provide much needed implant supply support during the pandemic although factors beyond their control have led to interruptions and delays to elective surgery. Companies have continued to provide representatives in theatre in the manner required and preferred by surgeons and hospitals. The forum meets quarterly and is open to membership by all MTAA companies supplying orthopaedic products. The MTAA Orthopaedic Forum meetings are attended by representatives of 18 member companies – two new MTAA members joined the Forum in FY 2022. Activities this year included:

- Scheduled meetings with the Australian Orthopaedic Association (AOA) Presidential Line, the AOA CEO and the Director of the National Joint Replacement Registry, usually held quarterly.
- Renewal of the contract with KPMG for conduct of the MTAA Orthopaedic Market Survey for the next three-year period. The survey has 17 companies contributing data in the categories of hips, knees, shoulders, spine, trauma, sports and bone cement products.
- Submission to the AOA's governance review of the National Joint Replacement Registry (NJRR) in March 2022.
- Ad hoc meetings to discuss Prostheses List regrouping proposals prepared for the Department of Health and Ageing.

WORKING WITH MEMBERS

WORKING GROUPS

Industry Development Working Group

The Industry Development Working Group (formerly the Manufacturing Working Group (MWG)) is a group of members who research, develop, commercialise, manufacture and export MedTech within Australia. Although a small group, they work together to develop policy positions that promote the retention of intellectual property, sovereign manufacturing in Australia and increased domestic and foreign investment into the Australian medical technology sector.

In June 2022, the group underwent a rebrand and endorsed a new Terms of Reference to ensure a broader spectrum of industry activities are covered including manufacturing, R&D and domestic/foreign investment. Over the last year, the Industry Development Working Group successfully advocated to improve Australians' access to new devices and technologies. MTAA successfully represented local manufacturers in two ways:

1. Contributed positions for the MTAA pre-budget submission to provide support and advocacy for state and federal programs for local manufacturers; and
2. Successfully advocated for the Patent Box tax concession.

Connected Health Advisory Group

During the 2021-2022 Financial Year, the Connected Healthcare Advisory Group (CHAG) operated under their agreed purpose, mission, and position statement to continue to advance the three key areas of focus: Awareness, Thought Leadership (Advocacy and Engagement), and Reimbursement.

The CHAG provided a submission to the Australian Digital Health Agency in response to the draft National Healthcare Interoperability Plan which highlighted the lack of a clear reimbursement mechanism, competition amongst service providers which results in a barrier to interoperability, and lack of innovative health initiative uptake.

The CHAG also provided a submission in response to the Productivity Commission into Productivity which highlighted the current landscape and proposals for consideration, including a community funding scheme for connected devices, updated MBS connected health item numbers, integrating connected health solutions in Aged Care, review of the approaches to Health Technology Assessment for connected health interventions, additional connected health funding under the National Health Reform Agreements, and policy change to improve Australia's economic performance.

Clinical Advisory Group

Since 2004, MTAA has provided industry representatives to participate in meetings of Prostheses List (PL) Clinical Advisory Groups (CAG) responsible for considering listing applications. The role of these representatives is to contribute industry input and perspective to CAG meeting discussions when it is appropriate to do so. In the reporting year, MTAA had industry CAG representatives nominated to cover consideration of PL applications in the categories of hips, knees, specialist orthopaedic, spine, cardiac, cardio-thoracic, vascular, and ophthalmic. Each CAG convenes up to three times per year depending on the volume of applications in their category.

Cyber Security Working Group

The goal of the Cyber Security Working Group (CSWG) is to position the medical technology sector as the leader in solutions and resources to improve medical cybersecurity in Australia.

The CSWG aims to achieve this through stakeholder engagement with relevant government bodies (TGA, ACSC, state governments) and structured partnerships across the healthcare and cybersecurity sectors to accelerate adoption of improved practices, and on the technology and policy aspects of health cybersecurity.

Radiation Therapy Advisory Group

The Radiation Therapy Advisory Group is an alliance between medical technology vendors, cancer patient advocates, healthcare providers and oncology professionals to provide informed advice to government and to the general public about radiation therapy and associated health policy issues.

Research & Development Task Force

This Task Force is a joint membership of MTAA, Medicines Australia and AusBiotech members with a goal to work with Government on their various initiatives and to shape the Clinical Trials space in Australia to ensure Australia becomes a preferred location to conduct Clinical Trials.

220

**MEMBER REPRESENTATIVES
CONTRIBUTE TO THE WORK OF
MTAA COMMITTEES, FORUMS AND
WORKING GROUPS IN 2021-22.**

COMMITTEE MEMBERS REPRESENTATION

Code Authority

Pam Davis (Chair)	Independent
Jeff Soo (Board Director)	Terumo
Chris Czelecky (Board Director)	Olympus
Dawn DeCruz	Allergan
Midhat Saber	Johnson & Johnson
Emma Press	Medtronic
Kenneth Wong	Arthrex Australia Pty Ltd
Adam Wood	LifeHealthcare
Michael Baulch	Boston Scientific
Henry Ko	Consumer Health Forum
Dr John Quin	Royal Australasian College of Surgeons

Retired/Resigned:

Steven Flynn, Baxter Healthcare
Dominica McCann, Zimmer Biomet

Code Monitoring

Pam Davis (Chair)	Independent
Michelle Stewart	Device Technologies
Helen Roch	Johnson & Johnson
Rebecca Arthur	Medtronic Australasia Pty Ltd
Jenny Chau	Smith & Nephew Pty Ltd
Allison Fox	Boston Scientific
Megan Guy	Healthcare Professional

Retired/Resigned:

Jennifer Mew-Sum, Medtronic
Professor Mark Flynn, Centre for Innovation in Regional Health
Adam Wood, LifeHealthcare

Finance

Pat Williams (Co-Chair and Board Director)	Edwards Lifesciences
Joel Stuhler	LifeHealthcare
Marius Fourie	Abbott Medical

Retired/Resigned:

Susan Martin, Johnson & Johnson Medical
Heath Priestly, Device Technologies

Industry Policy

Kate King (Chair)	Medtronic Australasia Pty Ltd
Kirk Kikirekov (Vice Chair)	Prospitalia h-Trak
Daniel Kildea	Johnson & Johnson Medi-cal
Geethu Roshan Verghese	Boston Scientific
George Sidis	IDE Group
Michael Reynolds	BIOTRONIK
Neroli Manning	Cardinal Health
Paul Davies	Abbott Medical Pty Ltd
Rebecca Cortiula	Varian Australasia
Tansy Michael	Fresenius Medical Care
Nadine McArthur	Alcon
Nikki McNeil	Stryker

Retired/Resigned:

Ross Lane, Cook Medical
Matthew Malone, Stryker
Damon Mogridge, Smith+Nephew
Jane Crowe, Roche Diabetes Care Australia
Simon Williamson, Edwards Lifesciences
Naeema Mohamed, Zimmer Biomet
Clinton Lubke, Stryker

MedTech Conference

Pat Williams (Co-Chair and Board Director)	Edwards Lifesciences
Liz Carnabuci (Co-Chair and Board Director)	Medtronic Australasia
Charlotte Hart	Nevro
Caroline Hale	3M Australia Pty Ltd
Lisa Briscoe	Cook Medical
Louise Porter	Medtronic Australasia Pty Ltd
Ian Hyam	Smith & Nephew Pty Ltd
Amanda Watson	Varian Medical Systems

Retired/Resigned:

Alex Goldenstein, Stryker
Samantha Bailey, Varian Medical Systems
Nicola McAlpine, Medtronic Australasia
Sakeena Monopoli, Edwards Lifesciences
Chris Mills, Johnson & Johnson Medical

Public Affairs

Susan Martin (Chair and Board Director)	Johnson & Johnson Medical
Chris Szeleczy (Board Director)	Olympus
Kate King (Chair of IPC)	Medtronic Australasia Pty Ltd
Mahesh Datar (Chair of RAC)	Medtronic Australasia Pty Ltd
Michael Simmonds (Chair of RC)	Boston Scientific
Robyn Chu	Alcon
Michael Reynolds	BIOTRONIK
Fraser Cleave	LifeHealthcare
Polo Guilbert-Wright	Edwards Lifesciences
Justin Keenan	Cook Medical
Alison Croweller	Johnson & Johnson Medical
Liz Carnabuci	Medtronic Australasia Pty Ltd
Paul Davies	Abbott Medical
Christian Gabriel	B. Braun
Mark Taffa	Horten Medical
Jesse Braunberger	Bard
Jack Lancaster	Evolution Surgical
Clinton Lubcke	Stryker

Retired/Resigned:

Daniel Kildea, Johnson & Johnson Medical
Beth Roberts, KLS Martin Australia
Julia Wenner, Terumo Blood and Cell Technologies
Alex Best, Johnson & Johnson Medical
James Doyle, Stryker

Regulatory Affairs

Mahesh Datar (Chair)	Medtronic Australasia Pty Ltd
George Faithfull (Vice Chair)	George Faithfull Advisory P/L
Elizabeth Van Den Akker	Abbott Vascular
Renee Cotta	Boston Scientific
Ruth Shennan	Device Technologies
Rebecca Gaudin	Johnson & Johnson
Sarah Botros	Stryker
Fleur Winslade	Terumo
Juliana William	Baxter Healthcare
Maneesha Pillay	Edwards Lifesciences
Sarah Timms	Fresenius Medical Care
Romit Singh	Arthrex Australia Pty Ltd
Leanne Hartge	3M Australia Pty Ltd
Falko Thiele	BIOTRONIK Australia
Giselle Rayman	Cardinal Health
Lynda Notting	Commercial Eyes Pty Ltd
Richard Malyn	Lima Orthopaedics
Sahil Talwar	Zimmer Biomet
Hemangi Malde	Cook Australia

Retired/Resigned:

Jason Aldworth, 3DMEDITech
Grant Woolcott, Teleflex Medical
Naeema Mohamed, Zimmer Biomet
Rachel Patrick, Mölnlycke Health Care
Grace Shen, Alcon Laboratories
Sue Hunter, Abbott Medical
Iryny Ibrahim, Smith & Nephew

Reimbursement

Michael Simmonds (Chair)	Boston Scientific
Sarah Griffin	Medtechnique Consulting
Michael Reynolds	BIOTRONIK
Joel Parrish	Elekta
Rachael Todd	Edwards Lifesciences
Maggie Dowrick	Cook Medical
George Papadopoulos	Lucid Health Consulting
Nicole Barnett	Johnson & Johnson Medical
Rachael Hook	B Braun
Marius van den Berg	Bard Australia Pty Ltd
Joanne Burnett	Commercial Eyes Pty Ltd
John Gillespie	Abbott Medical
Doug Symonds	Medtronic Australasia Pty Ltd
Sheryl Dunlop	Zimmer Biomet
Sarah Botros	Stryker
Kristy Hardy	LifeHealthcare

Retired/Resigned:

Simon Norris, Device Technologies
Georgia Psarros, Baxter Healthcare
Sebnem Erdol, Abbott Medical
Adam Gordoio, Covance
Brad Robinson, 3-D Matrix Medical Technology
Tracey Doman, Abbott Medical
Lauren Dodd, Integra Lifesciences
Oona Reardon, Labcorp

Women in MedTech

Rebecca Cortiula (Chair and Board Director)	Varian Medical Systems
Liz Carnabuci (Board Director)	Medtronic
Eleni Spiridonis	Stryker
Casey Duggan	JEM Med
Catherine Wood	Medtronic
Fiona Sheppard	Johnson & Johnson
Jessica Blackman	3M Australia
Cathey Saha	Abbott Medical
Sofia Hernandez	Baxter Healthcare
Sue Hansford	Integra Neurosciences
Aurea Dumalaog	Bard
Beverly Green	Cardinal Health
Robyn Butterworth	B. Braun
Kelly Turner	Boston Scientific
Pat Callanan	Boston Scientific
Caitlin Chimes	Zimmer Biomet
Kirstyn Pickering	Device Technologies

Retired/Resigned:

Debora Houston, TRESP Recruitment
Diana Da Silva, Smith & Nephew
Novak Laforest, Olympus Australia
Kristin Dale, Cook Medical
Lyn Davies, Tunstall Australasia
Catherine Wood, Medtronic
Kimberly Hobbs, LivaNova
Michelle Vrab, Terumo Australia
Naeema Mohamed, Zimmer Biomet



Our work is to **champion medical technology for a healthier Australia**

When our work is done, **medical technology will be valued as a key driver of a healthier Australia.**

Medical Technology
Association of Australia



Medical Technology Association of Australia

4/97 Waterloo Road, Macquarie Park

Sydney, Australia

P +61 (0) 2 9900 0600

E reception@mtaa.org.au

www.mtaa.org.au



Medical Technology
ASSOCIATION OF AUSTRALIA